This section contains information intended for healthcare professionals. Please certify that you are a healthcare professional.

Please indicate your country of residence:

What language is your preference?

Sebia has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the FLC Kappa & Lambda assays.

These are the first EIA tests receiving 510(k) from the FDA for the quantitative detection of both kappa and lambda free light chains (FLC) in human serum specimens, intended for both aid of diagnosis and monitoring of #Multiple Myeloma and Immunoglobulin Light-Chain (AL-) amyloidosis.

To learn more, consult the press release :

DOWNLOAD THE PRESS RELEASE